IMM 1.64% 30.0¢ immutep limited

Media, page-102

  1. 770 Posts.
    lightbulb Created with Sketch. 100
    https://www.businesswire.com/news/home/20240815340200/en/IMFINZI®-durvalumab-granted-Priority-Review-and-Breakthrough-Therapy-Designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-US

    may interest some
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.